Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Berobenatide

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Pfizer · Phase 3 · Recruiting · Enrollment 300

NCT07792954

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Berobenatide Medium Maintenance Dosen/rn/rn/rn/r
Placebo Matched to Low-Dose Berobenatiden/rn/rn/rn/r
Berobenatide Low Maintenance Dosen/rn/rn/rn/r
Berobenatide High Maintenance Dosen/rn/rn/rn/r
Placebo Matched to Medium-Dose Berobenatiden/rn/rn/rn/r
Placebo Matched to High-Dose Berobenatiden/rn/rn/rn/r

Not shown

  • Berobenatide Medium Maintenance Dose: endpoint not reported
  • Placebo Matched to Low-Dose Berobenatide: endpoint not reported
  • Berobenatide Low Maintenance Dose: endpoint not reported
  • Berobenatide High Maintenance Dose: endpoint not reported
  • Placebo Matched to Medium-Dose Berobenatide: endpoint not reported
  • Placebo Matched to High-Dose Berobenatide: endpoint not reported